Three/CD leading/VBG drug/NN companies/NNS reported/VBD robust/JJ third-quarter/NN earnings/NNS ,/, bolstered/VBN by/IN strong/JJ sales/NNS of/IN newer/JJR ,/, big-selling/JJ prescriptions/NNS drugs/NNS that/WDT provide/VBP hefty/JJ profit/NN margins/NNS ./.
Merck/NNP &/CC Co./NNP reported/VBD a/DT #/CD %/NN increase/NN in/IN earnings/NNS ;/: Warner-Lambert/NNP Co./NNP 's/POS profit/NN rose/VBD #/CD %/NN and/CC Eli/NNP Lilly/NNP &/CC Co./NNP 's/POS net/JJ income/NN rose/VBD #/CD %/NN ./.
The/DT results/NNS were/VBD in/IN line/NN with/IN analysts/NNS '/POS expectations/NNS ./.
Merck/NNP &/CC Co/NNP ./.
Merck/NNP ,/, Rahway/NNP ,/, N.J./NNP ,/, continued/VBD to/TO lead/VB the/DT industry/NN with/IN a/DT strong/JJ sales/NNS performance/NN in/IN the/DT human/NN and/CC animal/NN health-products/NNS segment/NN ./.
A/DT stronger/JJR U.S./NNP dollar/NN reduced/VBD third-quarter/NN and/CC first-nine-month/JJ sales/NNS growth/NN #/CD %/NN and/CC #/CD %/NN ,/, respectively/RB ./.
International/JJ sales/NNS accounted/VBD for/IN #/CD %/NN of/IN total/JJ company/NN sales/NNS for/IN the/DT nine/CD months/NNS ,/, compared/VBN with/IN #/CD %/NN a/DT year/NN earlier/RBR ./.
Sales/NNS for/IN the/DT quarter/NN rose/VBD to/TO $/$ #.#/CD billion/CD from/IN $/$ #.#/CD billion/CD ./.
Mevacor/NNP ,/, Merck/NNP 's/POS new/JJ cholesterol-lowering/JJ drug/NN ,/, had/VBD higher/JJR sales/NNS than/IN any/DT other/JJ prescription/NN medicine/NN has/VBZ ever/RB achieved/VBN in/IN the/DT U.S./NNP in/IN the/DT year/NN following/VBG introduction/NN ,/, the/DT company/NN said/VBD ./.
The/DT drug/NN was/VBD introduced/VBN in/IN West/NNP Germany/NNP this/DT year/NN ./.
Intense/JJ competition/NN ,/, however/RB ,/, led/VBD to/TO unit/NN sales/NNS declines/NNS for/IN a/DT group/NN of/IN Merck/NNP 's/POS established/VBN human/NN and/CC animal-health/NN products/NNS ,/, including/VBG Aldomet/NNP and/CC Indocin/NNP ./.
In/IN New/NNP York/NNP Stock/NNP Exchange/NNP composite/JJ trading/NN yesterday/NN ,/, Merck/NN shares/NNS closed/VBD at/IN $/$ #.#/CD ,/, up/IN #/CD cents/NNS ./.
Warner-Lambert/NNP Co/NNP ./.
Warner-Lambert/NNP ,/, Morris/NNP Plains/NNP ,/, N.J./NNP ,/, reported/VBD sales/NNS that/WDT were/VBD a/DT record/NN for/IN any/DT quarter/NN and/CC the/DT eighth/JJ quarter/NN in/IN a/DT row/NN of/IN #/CD %/NN or/CC more/JJR per-share/JJ earnings/NNS growth/NN ./.
Spurred/VBN by/IN growth/NN in/IN world-wide/JJ sales/NNS of/IN the/DT company/NN 's/POS prescription/NN drugs/NNS ,/, Warner-Lambert/NNP said/VBD #/CD will/MD be/VB the/DT best/JJS year/NN in/IN its/PRP$ history/NN ,/, with/IN per-share/JJ earnings/NNS expected/VBN to/TO increase/VB more/JJR than/IN #/CD %/NN to/TO about/IN $/$ #.#/CD ./.
Sales/NNS for/IN the/DT quarter/NN rose/VBD to/TO $/$ #.#/CD billion/CD from/IN $/$ #.#/CD billion/CD ./.
Prescription-drug/NN world-wide/JJ sales/NNS rose/VBD #/CD %/NN in/IN the/DT quarter/NN to/TO $/$ #/CD million/CD ;/: U.S./NNP sales/NNS rose/VBD #/CD %/NN ./.
The/DT segment/NN 's/POS growth/NN was/VBD led/VBN by/IN sales/NNS of/IN the/DT cardiovascular/JJ drugs/NNS Lopid/NNP ,/, a/DT lipid/NN regulator/NN ,/, and/CC Dilzem/NNP ,/, a/DT calcium/NN channel/NN blocker/NN ./.
World-wide/JJ sales/NNS of/IN Warner-Lambert/NNP 's/POS non-prescription/JJ health-care/NN products/NNS ,/, such/JJ as/IN Halls/NNP cough/NN tablets/NNS ,/, Rolaids/NNP antacid/NN ,/, and/CC Lubriderm/NNP skin/NN lotion/NN ,/, increased/VBD #/CD %/NN to/TO $/$ #/CD million/CD in/IN the/DT third/JJ quarter/NN ;/: U.S./NNP sales/NNS rose/VBD #/CD %/NN ./.
Confectionery/JJ products/NNS sales/NNS also/RB had/VBD strong/JJ growth/NN in/IN the/DT quarter/NN ./.
World-wide/JJ sales/NNS of/IN Trident/NNP gum/NN ,/, Certs/NNP breath/NN mints/NNS ,/, and/CC Clorets/NNP gum/NN and/CC breath/NN mints/NNS ,/, increased/VB #/CD %/NN to/TO $/$ #/CD million/CD ./.
Warner-Lambert/NNP shares/NNS closed/VBD at/IN $/$ #.#/CD a/DT share/NN ,/, up/IN $/$ #.#/CD ,/, in/IN Big/NNP Board/NNP composite/JJ trading/NN yesterday/NN ./.
Eli/NNP Lilly/NNP &/CC Co/NNP ./.
Lilly/NNP attributed/VBD record/NN third-quarter/JJ and/CC nine-month/JJ results/NNS to/TO world-wide/JJ gains/NNS for/IN pharmaceuticals/NNS ,/, medical/JJ instruments/NNS and/CC plant-science/NN products/NNS despite/IN poor/JJ exchange/NN rates/NNS for/IN the/DT dollar/NN that/WDT slowed/VBD sales/NNS abroad/RB ./.
Earnings/NNS continued/VBD to/TO pace/VB sales/NNS because/IN of/IN a/DT lower/JJR tax/NN rate/NN ,/, profit/NN from/IN the/DT renegotiation/NN of/IN the/DT debt/NN instrument/NN received/VBN from/IN Faberge/NNP Inc./NNP in/IN connection/NN with/IN Lilly/NNP 's/POS sale/NN of/IN Elizabeth/NNP Arden/NNP Inc./NNP in/IN #/CD ,/, and/CC net/JJ proceeds/NNS from/IN the/DT settlement/NN of/IN patent/NN litigation/NN at/IN Lilly/NNP 's/POS Hybritech/NNP Inc./NNP unit/NN ./.
Third-quarter/NN sales/NNS of/IN the/DT Indianapolis/NNP ,/, Ind./NNP ,/, company/NN rose/VBD #/CD %/NN to/TO $/$ #.#/CD billion/CD from/IN $/$ #.#/CD million/CD ./.
Nine-month/JJ sales/NNS grew/VBD #/CD %/NN to/TO $/$ #.#/CD billion/CD from/IN $/$ #.#/CD billion/CD a/DT year/NN earlier/RBR ./.
Sales/NNS of/IN Prozac/NNP ,/, an/DT anti-depressant/NN ,/, led/VBD drug-sales/NNS increases/NNS ./.
Higher/JJR sales/NNS of/IN pesticides/NNS and/CC other/JJ plant-science/NN products/NNS more/RBR than/IN offset/VBP a/DT slight/JJ decline/NN in/IN the/DT sales/NNS of/IN animal-health/NN products/NNS to/TO fuel/VB the/DT increase/NN in/IN world-wide/JJ agricultural/JJ product/NN sales/NNS ,/, Lilly/NNP said/VBD ./.
Advanced/NNP Cardiovascular/NNP Systems/NNPS Inc./NNP and/CC Cardiac/NNP Pacemakers/NNPS Inc./NNP units/NNS led/VBD growth/NN in/IN the/DT medical-instrument/JJ systems/NNS division/NN ./.
Lilly/NNP shares/NNS closed/VBD yesterday/NN in/IN composite/JJ trading/NN on/IN the/DT Big/NNP Board/NNP at/IN $/$ #.#/CD ,/, down/IN #.#/CD cents/NNS ./.
